2026-05-10T16:19:53Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/201542024-11-28T18:07:45Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16961col_20.500.12105_16967col_20.500.12105_16978col_20.500.12105_16984

00925njm 22002777a 4500 dc Noriega, Victor author Martinez-Laperche, Carolina author Buces, Elena author Sanchez-Hernandez, Noemi author Martin-Antonio, Beatriz author Guillem, Vicent author Bosch-Vizcaya, Anna author Bento, Leyre author Gonzalez-Rivera, Milagros author Balsalobre, Pascual author Kwon, Mi author Serrano, David author Gayoso, Jorge author de la Cámara, Rafael author Brunet, Salut author Rojas-Contreras, Rafael author Nieto, Jose B. author Martinez, Carmen author Gonzalez, Marcos author Espigado, Ildefonso author Vallejo, Juan C. author Sampol Mayol, Antonia author Jimenez-Velasco, Antonio author Urbano-Ispizua, Alvaro author Solano, Carlos author Gallardo, David author Diez-Martin, Jose L author Buno, Ismael author Spanish Hematopoietic Stem Cell Tr author 2015-10-16 The FOXP3 gene encodes for a protein (Foxp3) involved in the development and functional activity of regulatory T cells (CD4+/CD25+/Foxp3+), which exert regulatory and suppressive roles over the immune system. After allogeneic stem cell transplantation, regulatory T cells are known to mitigate graft versus host disease while probably maintaining a graft versus leukemia effect. Short alleles (<=(GT)(15)) for the (GT)(n) polymorphism in the promoter/enhancer of FOXP3 are associated with a higher expression of FOXP3, and hypothetically with an increase of regulatory T cell activity. This polymorphism has been related to the development of auto-or alloimmune conditions including type 1 diabetes or graft rejection in renal transplant recipients. However, its impact in the allo-transplant setting has not been analyzed. In the present study, which includes 252 myeloablative HLA-identical allo-transplants, multivariate analysis revealed a lower incidence of grade III-IV acute graft versus host disease (GVHD) in patients transplanted from donors harboring short alleles (OR = 0.26, CI 0.08-0.82, p = 0.021); without affecting chronic GVHD or graft versus leukemia effect, since cumulative incidence of relapse, event free survival and overall survival rates are similar in both groups of patients. Noriega V, Martinez-Laperche C, Buces E, Pion M, Sanchez-Hernandez N, Martin-Antonio B, et al. The Genotype of the Donor for the (GT)(n) Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. PLoS One. 2015 Oct 16;10(10):e0140454. 10.1371/journal.pone.0140454 1932-6203 PloS One http://hdl.handle.net/20.500.13003/10659 26473355 L607132865 2-s2.0-84949220859 http://hdl.handle.net/20.500.12105/20154 363185500054 The Genotype of the Donor for the (GT)(n) Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation